Agilent Technologies, Inc. (A)

NYSE: A · IEX Real-Time Price · USD
+0.65 (0.55%)
Jul 1, 2022 4:03 PM EDT - Market closed

Company Description

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.

The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies.

The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide.

It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics.

The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services.

The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquar

Agilent Technologies, Inc.
Agilent Technologies Logo
Country United States
Founded 1999
IPO Date Nov 18, 1999
Industry Life Sciences Tools & Services
Sector Health Care
Employees 17,400
CEO Michael McMullen

Contact Details

5301 Stevens Creek Blvd
Santa Clara, California 95051-7201
United States
Phone 800 227 9770

Stock Details

Ticker Symbol A
Exchange NYSE
Fiscal Year November - October
Reporting Currency US Dollars
CIK Code 0001090872
CUSIP Number 00846U101
ISIN Number US00846U1016
Employer ID 77-0518772
SIC Code 3826

Key Executives

Name Position
Michael R. McMullen Chief Executive Officer, President and Director
Robert W. McMahon Senior Vice President and Chief Financial Officer
Jacob Thaysen Senior Vice President and President of Life Sciences and Applied Markets Group
Samraat S. Raha Senior Vice President and President of Diagnostics and Genomics Group
Padraig McDonnell Senior Vice President and President of Agilent Cross Lab Group
Rodney Gonsalves Principal Accounting Officer, Vice President and Corporate Controller
Dr. Darlene J. S. Solomon Ph.D. Chief Technology Officer and Senior Vice President
Michael Tang Senior Vice President, General Counsel and Secretary
Dominique P. Grau Senior Vice President of Human Resources and Global Communications
Allison Ballmer Senior Vice President of Strategy and Corporate Development

Latest SEC Filings

Date Type Title
Jul 1, 2022 4 Statement of changes in beneficial ownership of securities
Jun 6, 2022 4 Statement of changes in beneficial ownership of securities
May 27, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
May 25, 2022 SD Specialized disclosure report
May 24, 2022 8-K Current report
May 20, 2022 4 Statement of changes in beneficial ownership of securities
May 17, 2022 4 Statement of changes in beneficial ownership of securities
May 17, 2022 4 Statement of changes in beneficial ownership of securities
May 5, 2022 4 Statement of changes in beneficial ownership of securities
Apr 18, 2022 8-K Current report